Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

TRPV3 modulates nociceptive signaling through peripheral and supraspinal sites in rats.

McGaraughty S, Chu KL, Xu J, Leys L, Radek RJ, Dart MJ, Gomtsyan A, Schmidt RG, Kym PR, Brederson JD.

J Neurophysiol. 2017 Aug 1;118(2):904-916. doi: 10.1152/jn.00104.2017. Epub 2017 May 3.

2.

Disturbances in slow-wave sleep are induced by models of bilateral inflammation, neuropathic, and postoperative pain, but not osteoarthritic pain in rats.

Leys LJ, Chu KL, Xu J, Pai M, Yang HS, Robb HM, Jarvis MF, Radek RJ, McGaraughty S.

Pain. 2013 Jul;154(7):1092-102. doi: 10.1016/j.pain.2013.03.019. Epub 2013 Mar 15.

PMID:
23664655
3.

Rats housed on corncob bedding show less slow-wave sleep.

Leys LJ, McGaraughty S, Radek RJ.

J Am Assoc Lab Anim Sci. 2012 Nov;51(6):764-8.

4.

Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.

Radek RJ, Robb HM, Stevens KE, Gopalakrishnan M, Bitner RS.

J Pharmacol Exp Ther. 2012 Dec;343(3):736-45. doi: 10.1124/jpet.112.197970. Epub 2012 Sep 17.

PMID:
22988063
5.

Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.

Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD.

J Pharmacol Exp Ther. 2012 Oct;343(1):233-45. doi: 10.1124/jpet.112.194126. Epub 2012 Jul 19.

PMID:
22815533
6.

The Behavioral Assessment of Sensorimotor Processes in the Mouse: Acoustic Startle, Sensory Gating, Locomotor Activity, Rotarod, and Beam Walking.

Curzon P, Zhang M, Radek RJ, Fox GB.

In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 8.

7.

Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.

Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG.

Curr Pharm Des. 2010 Jan;16(3):309-22. Review.

PMID:
20109141
8.

Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.

Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, Ween H, Curtis MP, Sarris KA, Gfesser GA, El-Kouhen R, Robb HM, Radek RJ, Marsh KC, Bunnelle WH, Gopalakrishnan M.

J Med Chem. 2009 May 28;52(10):3377-84. doi: 10.1021/jm9003818.

PMID:
19419141
9.

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Tietje KR, Anderson DJ, Bitner RS, Blomme EA, Brackemeyer PJ, Briggs CA, Browman KE, Bury D, Curzon P, Drescher KU, Frost JM, Fryer RM, Fox GB, Gronlien JH, Håkerud M, Gubbins EJ, Halm S, Harris R, Helfrich RJ, Kohlhaas KL, Law D, Malysz J, Marsh KC, Martin RL, Meyer MD, Molesky AL, Nikkel AL, Otte S, Pan L, Puttfarcken PS, Radek RJ, Robb HM, Spies E, Thorin-Hagene K, Waring JF, Ween H, Xu H, Gopalakrishnan M, Bunnelle WH.

CNS Neurosci Ther. 2008 Spring;14(1):65-82. doi: 10.1111/j.1527-3458.2008.00037.x. Review.

10.

Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.

Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, Li J, Malysz J, Markosyan S, Marsh K, Meyer MD, Nikkel AL, Radek RJ, Robb HM, Timmermann D, Sullivan JP, Gopalakrishnan M.

J Neurosci. 2007 Sep 26;27(39):10578-87.

11.

Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating.

Radek RJ, Miner HM, Bratcher NA, Decker MW, Gopalakrishnan M, Bitner RS.

Psychopharmacology (Berl). 2006 Jul;187(1):47-55. Epub 2006 May 6.

PMID:
16767415
12.

Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity.

Giardina WJ, Dart MJ, Harris RR, Bitner RS, Radek RJ, Fox GB, Chemburkar SR, Marsh KC, Waring JF, Hui JY, Chen J, Curzon P, Grayson GK, Komater VA, Ku Y, Lockwood M, Miner HM, Nikkel AL, Pan JB, Pu YM, Wang L, Bennani Y, Durmuller N, Jolly R, Roux S, Sullivan JP, Decker MW.

Epilepsia. 2005 Sep;46(9):1349-61.

13.

Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.

Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S23-4. No abstract available.

PMID:
15928819
14.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.

Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. Epub 2004 Dec 17.

PMID:
15608077
15.
16.

The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats.

Radek RJ, Decker MW, Jarvis MF.

Brain Res. 2004 Nov 5;1026(1):74-83.

PMID:
15476699
17.

Cognition enhancing effects of novel H(3) receptor (H(3)R) antagonists in several animal models.

Fox GB, Pan JB, Lewis AM, Browman KE, Komater VA, Buckley MJ, Curzon P, Radek RJ, Faghih R, Esbenshade TA, Cowart MD, Decker MW, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S49-50. Epub 2004 Mar 5. No abstract available.

PMID:
15054614
18.

Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization.

Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2003 Jun;305(3):897-908. Epub 2003 Feb 20.

PMID:
12606600
19.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.

Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP.

J Pharmacol Exp Ther. 1998 May;285(2):787-94.

PMID:
9580627
20.

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.

Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J, et al.

Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:50-61.

PMID:
8534424
21.

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.

Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT, et al.

J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.

PMID:
7913497
22.

Characterization of high voltage spindles and spatial memory in young, mature and aged rats.

Radek RJ, Curzon P, Decker MW.

Brain Res Bull. 1994;33(2):183-8.

PMID:
8275337
23.

Effects of nicotine on cortical high voltage spindles in rats.

Radek RJ.

Brain Res. 1993 Oct 15;625(1):23-8.

PMID:
8242397
24.
25.

Effects of imipramine on the nocturnal behavior of bilateral olfactory bulbectomized rats.

Giardina WJ, Radek RJ.

Biol Psychiatry. 1991 Jun 15;29(12):1200-8.

PMID:
1888801

Supplemental Content

Loading ...
Support Center